DrugPatentWatch Database Preview

Insulin glargine recombinant - Biologic Drug Details

Email this page to a colleague

Tradenames:	4
Patents:	106
Applicants:	2
BLAs:	2
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for insulin glargine recombinant
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for insulin glargine recombinant

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Amrita Institute of medical sciences and research Center kochi	Phase 4
Jawaharlal nehru institute of medical education and research Puducherry	Phase 4
Hinduja hospitals mumbai	Phase 4

Identify key patents and potential future biosimilar entrants

Case Name	Date
SANOFI-AVENTIS U.S. LLC v. MYLAN N v.	2017-10-24
SANOFI-AVENTIS U.S. LLC v. MERCK SHARP & DOHME CORP.	2017-08-08
Allergan Sales, LLC v. Teva Pharmaceuticals USA, Inc.	2016-11-30

These patents were extracted from company disclosures

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Sanofi Aventis Us	LANTUS	insulin glargine recombinant	INJECTABLE;INJECTION	021081	001	2000-11-17	Start Trial	Medimpex Ets. (Balzers, LI)	2012-02-21	RX		company
Sanofi Aventis Us	LANTUS	insulin glargine recombinant	INJECTABLE;INJECTION	021081	001	2000-11-17	Start Trial	Medimpex Ets (LI)	2013-04-23	RX		company
Sanofi Aventis Us	LANTUS	insulin glargine recombinant	INJECTABLE;INJECTION	021081	001	2000-11-17	Start Trial	Hoechst Aktiengesellschaft (Frankfurt am Main, DE)	2014-08-12	RX		company
Sanofi Aventis Us	LANTUS SOLOSTAR	insulin glargine recombinant	INJECTABLE;INJECTION	021081	002	2000-11-17	Start Trial	Medimpex Ets. (Balzers, LI)	2012-02-21	RX		company
Sanofi Aventis Us	LANTUS SOLOSTAR	insulin glargine recombinant	INJECTABLE;INJECTION	021081	002	2000-11-17	Start Trial	Medimpex Ets (LI)	2013-04-23	RX		company
Sanofi Aventis Us	LANTUS SOLOSTAR	insulin glargine recombinant	INJECTABLE;INJECTION	021081	002	2000-11-17	Start Trial	Hoechst Aktiengesellschaft (Frankfurt am Main, DE)	2014-08-12	RX		company
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

These patents were identified by searching patent claims

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Sanofi Aventis Us	LANTUS	insulin glargine recombinant	INJECTABLE;INJECTION	021081	001	2000-11-17	Start Trial	Cognis Gesellschaft fuer Biotechnologie mbH (Duesseldorf, DE)	2040-04-01	RX		search
Sanofi Aventis Us	LANTUS	insulin glargine recombinant	INJECTABLE;INJECTION	021081	001	2000-11-17	Start Trial	Lipocine, Inc. (Salt Lake City, UT)	2039-02-26	RX		search
Sanofi Aventis Us	LANTUS	insulin glargine recombinant	INJECTABLE;INJECTION	021081	001	2000-11-17	Start Trial	Lipocine Inc. (Salt Lake City, UT)	2039-02-26	RX		search
Sanofi Aventis Us	LANTUS	insulin glargine recombinant	INJECTABLE;INJECTION	021081	001	2000-11-17	Start Trial	Lipocine, Inc. (Salt Lake City, UT)	2039-02-26	RX		search
Sanofi Aventis Us	LANTUS	insulin glargine recombinant	INJECTABLE;INJECTION	021081	001	2000-11-17	Start Trial	Novo Nordisk, Inc. (Bagsvaerd, DK)	2020-06-23	RX		search
Sanofi Aventis Us	LANTUS	insulin glargine recombinant	INJECTABLE;INJECTION	021081	001	2000-11-17	Start Trial	Amylin Pharmaceuticals, Inc. (San Diego, CA)	2018-01-09	RX		search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

Subscribe to access the full database, or Start Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
213	Luxembourg	Start Trial	PRODUCT NAME: INSULINE DEGLUDEC SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/12/807/001-4-5-7-8-9-12-13-15 TRESIBA 20130123
C/GB00/022	United Kingdom	Start Trial	PRODUCT NAME: INSULIN GLARGINE (LANTUS) OPTIONALLY IN THE FORM OF ESTERS THEREOF OR PHYSIOLOGICALLY TOLERATED SALTS THEREOF.; REGISTERED: UK EU/1/00/134/001 20000609; UK EU/1/00/134/002 20000609; UK EU/1/00/134/003 20000609; UK EU/1/00/134/004 20000609; UK EU/1/00/134/005 20000609; UK EU/1/00/134/006 20000609; UK EU/1/00/134/007 20000609
199011	Germany	Start Trial	PRODUCT NAME: KRISTALLE, ENTHALTEND ASP B28 HUMAN-INSULIN UND PROTAMIN; REGISTRATION NO/DATE: EU/1/00/142/001-008 20000801
91020-8 0090020-9	Sweden	Start Trial	PRODUCT NAME: LANTUS - INSULIN GLARGIN; REGISTRATION NO/DATE: EU/1/00/134/001 20000609
2017020,C2498802	Lithuania	Start Trial	PRODUCT NAME: INSULINAS GLARGINAS + LIKSISENATIDAS; REGISTRATION NO/DATE: EU/1/16/1157 20170111
/2005	Austria	Start Trial	PRODUCT NAME: NOVOMIX 50 - SUSPENSION, ENTHALTEND LOESLICHES INSULIN ASPART UND PROTAMINKRISTALLISIERTES INSULIN ASPART IM VERHAELTNIS 50:50; REGISTRATION NO/DATE: EU/1/00/142/011 - EU/1/00/142/016 20051005
>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description